Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets: 2011-2025

Historic Non-Current Assets for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $4.5 million.

  • Niagen Bioscience's Non-Current Assets rose 3.08% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 3.08%. This contributed to the annual value of $4.2 million for FY2024, which is 23.09% down from last year.
  • As of Q3 2025, Niagen Bioscience's Non-Current Assets stood at $4.5 million, which was down 6.67% from $4.8 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Non-Current Assets high stood at $8.9 million for Q4 2021, and its period low was $4.2 million during Q4 2024.
  • For the 3-year period, Niagen Bioscience's Non-Current Assets averaged around $5.3 million, with its median value being $5.1 million (2024).
  • In the last 5 years, Niagen Bioscience's Non-Current Assets soared by 45.54% in 2021 and then slumped by 30.37% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Non-Current Assets stood at $8.9 million in 2021, then fell by 16.17% to $7.5 million in 2022, then fell by 27.50% to $5.4 million in 2023, then fell by 23.09% to $4.2 million in 2024, then climbed by 3.08% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.8 million for Q2 2025, and $5.1 million during Q1 2025.